Exuma Biotech
Grand Cayman
About Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors. They develop new tools for the patient’s immune system to fight various solid tumor malignancies, such as renal cell carcinoma, soft tissue sarcoma, gastric cancer, and others. It was founded in 2015 and headquartered in Grand Cayman, Midland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $107.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2021)
- Website: exumabio.com
- Phone: 1-345-232-0566
Industries & Categories
Big Data, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/exuma-biotech-15102 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.